Skip to content

Linde plc Ordinary Shares (LIN) - Stock Report

Informational research — not investment advice.Full disclaimer

Informational research — not investment advice. Generated in part by AI and may contain errors; not a personal recommendation, solicitation, or offer. ReasyPort is not an authorised or regulated investment firm. Market data may be delayed or inaccurate. Capital is at risk and past performance does not guarantee future results — do your own research and consult a licensed adviser.

Full disclaimer
LIN

Linde plc Ordinary Shares

ReasyPort View: Demanding Watchlist — Contracted Cash Conversion Proof Required

Summary

At the 11 June 2026 close of $515.44, Linde trades about 17.6% above the selected fair value of $438.32. The business is not the objection: Linde is a high-quality industrial gas compounder with strong customer relationships, pricing discipline and resilient margins. The price already asks owners to underwrite contract protection, project execution and cash conversion through a heavier capex cycle.

Latest Proof Snapshot

The latest proof is solid but not clean enough to remove the valuation burden. In Q1 2026, sales were $8.781bn, up 8% year over year, with underlying sales up 3% from 2% price attainment and 1% volumes, helped by project start-ups. Reported operating profit was $2.439bn; adjusted operating profit was $2.630bn, up 8%, and adjusted operating margin was 30.0%, down only 10 bps despite challenging industrial conditions. Reported diluted EPS was $3.98 and adjusted diluted EPS was $4.33, with the main adjustment tied to Linde AG purchase-accounting impacts and cost-reduction or other charges. Q1 operating cash flow was $2.240bn; after $1.342bn of capex, company-reported free cash flow was $898m. Single-quarter shareholder returns of $1.545bn exceeded that post-capex cash by about $647m, so the cash-coverage test remains a pacing signal rather than a full-year capital-allocation indictment. Management guided Q2 2026 adjusted diluted EPS to $4.40-$4.50 and FY2026 adjusted diluted EPS to $17.60-$17.90, with capex of $5.0bn-$5.5bn to support growth and maintenance, including a $7.1bn contractual sale-of-gas project backlog.

Market Snapshot

The key macro issue is not industrial exposure in isolation, but whether Linde can turn a roughly $7.1 billion sale-of-gas backlog into post-capex free cash flow while energy pass-through, plant loading and project timing protect adjusted operating margin through a $5.0 billion-$5.5 billion capex year.

Business Overview

What The Company Actually Does

Linde is the largest global industrial gas company, serving chemicals and energy, manufacturing, electronics, healthcare, food and beverage, metals, mining and other process industries. Its products include atmospheric gases such as oxygen, nitrogen and argon, plus process and specialty gases including hydrogen, helium, carbon dioxide and electronic gases. These are embedded in customer production, safety, purity, cooling, refining, medical and manufacturing processes.

How The Business Is Organized

The delivery model matters as much as the molecule. Large customers are served by on-site plants and pipeline networks, typically under long-term agreements with fixed charges, minimum volume commitments and energy pass-through features. Merchant liquid customers receive gases by truck under medium-duration contracts. Smaller packaged-gas customers buy cylinders and related services. The stack is both capital intensive and resilient: assets are funded before the cash stream arrives, but switching costs and reliability requirements protect renewal economics.

What Management Appears To Be Prioritizing

Engineering is the smaller but strategically important layer. It builds air-separation, hydrogen, synthesis-gas and related facilities for third parties and Linde's own network. Its role is project execution, technology control and new gas capacity; the value bridge is industrial gas contracts converting backlog and price attainment into durable cash after capex.

🔒

Sign in to read the full report

Create a free account to unlock the rest of this report and access all published research.